FHA
APLS

First Horizon Advisors’s Apellis Pharmaceuticals APLS Stock Holding History

First Horizon Advisors’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-863
Closed -$24.9K – 2277
2024
Q3 		$24.9K Sell
863
-33
-4% -$1.22K ﹤0.01% 1278
2024
Q2 		$34.4K Buy
896
+185
+26% +$8.38K ﹤0.01% 1085
2024
Q1 		$41.8K Buy
711
+39
+6% +$2.49K ﹤0.01% 1034
2023
Q4 		$40.2K Buy
672
+23
+4% +$1.17K ﹤0.01% 1042
2023
Q3 		$24.7K Buy
649
+265
+69% +$11.6K ﹤0.01% 1158
2023
Q2 		$35K Buy
384
+29
+8% +$2.5K ﹤0.01% 1040
2023
Q1 		$23.4K Buy
+355
New +$20.5K ﹤0.01% 1205
2021
Q4 		– Sell
-4
Closed – – 2249
2021
Q3 		$0 Buy
+4
New +$225 ﹤0.01% 2269

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

First Horizon Advisors's APLS Position: Q4 2024 in Review

First Horizon Advisors sold out of Apellis Pharmaceuticals (APLS) in Q4 2024, closing a stake of 863 shares — an estimated $24.9K sold.

First Horizon Advisors first reported a position in APLS in Q3 2021 and held it in 8 quarters. The position peaked at $41.8K in Q1 2024. 260 funds tracked by Wall St. Rank hold APLS as of Q4 2024.

  • First Horizon Advisors reported no remaining Apellis Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • First Horizon Advisors sold 863 Apellis Pharmaceuticals shares in Q4 2024, an estimated $24.9K.
  • First Horizon Advisors first reported a position in Apellis Pharmaceuticals in Q3 2021 and held it in 8 quarters.
  • First Horizon Advisors's Apellis Pharmaceuticals position peaked at $41.8K in Q1 2024.
  • 260 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2024.

Based on First Horizon Advisors's 13F filing for Q4 2024, filed 3 Feb 2025.